Spero Therapeutics, Inc. (SPRO)
1.22
+0.02
(+1.67%)
USD |
NASDAQ |
Sep 02, 16:00
1.225
0.00 (0.00%)
Pre-Market: 20:00
Spero Therapeutics Research and Development Expense (TTM) : 20.53M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.53M |
| March 31, 2026 | 27.77M |
| December 31, 2025 | 38.47M |
| September 30, 2025 | 61.71M |
| June 30, 2025 | 79.98M |
| March 31, 2025 | 93.03M |
| December 31, 2024 | 96.76M |
| September 30, 2024 | 84.44M |
| June 30, 2024 | 73.86M |
| March 31, 2024 | 59.30M |
| December 31, 2023 | 50.60M |
| September 30, 2023 | 48.80M |
| June 30, 2023 | 39.40M |
| March 31, 2023 | 38.12M |
| December 31, 2022 | 46.05M |
| September 30, 2022 | 48.49M |
| June 30, 2022 | 55.70M |
| Date | Value |
|---|---|
| March 31, 2022 | 62.13M |
| December 31, 2021 | 64.01M |
| September 30, 2021 | 59.85M |
| June 30, 2021 | 63.29M |
| March 31, 2021 | 64.44M |
| December 31, 2020 | 66.24M |
| September 30, 2020 | 78.66M |
| June 30, 2020 | 79.15M |
| March 31, 2020 | 75.71M |
| December 31, 2019 | 64.99M |
| September 30, 2019 | 48.68M |
| June 30, 2019 | 39.14M |
| March 31, 2019 | 34.49M |
| December 31, 2018 | 35.78M |
| September 30, 2018 | 39.16M |
| June 30, 2018 | 37.61M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Inovio Pharmaceuticals, Inc. | 47.16M |
| Fortress Biotech, Inc. | 1.186M |
| Kura Oncology, Inc. | 259.47M |
| Legend Biotech Corp. | 397.18M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |